Pharmacokinetic interaction between verapamil and metoprolol in the dog. Stereochemical aspects. 1991

S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle 98195.

The effect of verapamil co-administration on the hepatic first-pass clearance of metoprolol was investigated in dogs. Plasma concentration-time course of metoprolol enantiomers and urinary recovery of oxidative metabolites were determined after a single iv (0.51 mg/kg) and an oral (1.37 mg/kg) dose of deuterium-labeled pseudoracemic metoprolol, with or without concomitant administration of racemic verapamil (3 mg/kg). Verapamil inhibited both the systemic and oral clearance of metoprolol by about 50-70%. The first-pass effect of metoprolol was completely abolished after co-administration of verapamil, reflecting a marked alteration in the degree of hepatic extraction of metoprolol from intermediate to low. The hepatic clearance of metoprolol was slightly (S)-enantioselective (R/S ratio = 0.89 +/- 0.04) in control dogs. Inhibition of hepatic clearance of metoprolol by verapamil was selective towards (S)-metoprolol, such that the enantioselectivity in hepatic clearance toward (S)-metoprolol disappeared following verapamil co-administration (R/S ratio = 1.01 +/- 0.05). Urinary metabolite profiles indicated that O-demethylation and N-dealkylation were the major pathways of oxidative metabolism in the dog. alpha-Hydroxymetoprolol was a minor metabolite in urine. N-Dealkylation showed a strong preference for (S)-metoprolol, whereas O-demethylation and alpha-hydroxylation exhibited a modest selectivity toward (R)-metoprolol; hence, the slight (S)-enantioselectivity in the overall hepatic clearance. Comparison of metoprolol metabolite formation clearances in the absence or presence of verapamil co-administration showed that all three oxidative pathways were inhibited by 60-80%. The greater inhibition of hepatic clearance observed with (S)-metoprolol as compared to (R)-metoprolol was attributed to a significant (S)-enantioselective inhibition in the O-demethylation of metoprolol by verapamil.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008790 Metoprolol A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS. Beloc-Duriles,Betaloc,Betaloc-Astra,Betalok,CGP-2175,H 93-26,Lopressor,Metoprolol CR-XL,Metoprolol Succinate,Metoprolol Tartrate,Seloken,Spesicor,Spesikor,Toprol,Toprol-XL,Beloc Duriles,Betaloc Astra,CGP 2175,CGP2175,H 93 26,H 9326,Metoprolol CR XL,Toprol XL
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D003903 Deuterium The stable isotope of hydrogen. It has one neutron and one proton in the nucleus. Deuterons,Hydrogen-2,Hydrogen 2
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females

Related Publications

S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
September 1986, The American journal of cardiology,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
July 1987, Clinical pharmacology and therapeutics,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
October 1984, Postgraduate medical journal,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
October 2014, Antimicrobial agents and chemotherapy,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
October 2005, British journal of clinical pharmacology,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
January 2010, Drug metabolism letters,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
May 2000, Clinical pharmacology and therapeutics,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
January 1989, Biopharmaceutics & drug disposition,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
April 1975, Nucleic acids research,
S S Murthy, and W L Nelson, and D D Shen, and J M Power, and C M Cahill, and A J McLean
January 1987, Pharmacology,
Copied contents to your clipboard!